Im­munome stops Covid-19 work; Hookipa drops CMV vac­cine

Im­munome is look­ing for a part­ner for its Covid-19 an­ti­body cock­tail known as IMM-BCP-01, ac­cord­ing to its an­nu­al re­port re­leased Thurs­day morn­ing. Un­til then, it will stop fur­ther de­vel­op­ment of the can­di­date.

The Ex­ton, PA-based biotech had test­ed the an­ti­body cock­tail in a Phase Ib tri­al with an es­ti­mat­ed en­roll­ment of 36 peo­ple who have mild to mod­er­ate Covid-19, ac­cord­ing to a fed­er­al clin­i­cal tri­als data­base. The tri­al was run in col­lab­o­ra­tion with the US DoD and was meant to look at the safe­ty of the drug. Im­munome said there were no sig­nif­i­cant treat­ment-re­lat­ed ad­verse events.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters